Published in BMC Microbiol on August 12, 2008
Acquisition of aneuploidy provides increased fitness during the evolution of antifungal drug resistance. PLoS Genet (2009) 2.07
Patients with long-term oral carriage harbor high-persister mutants of Candida albicans. Antimicrob Agents Chemother (2009) 1.46
Frequent detection of 'azole' resistant Candida species among late presenting AIDS patients in northwest Ethiopia. BMC Infect Dis (2013) 1.02
Oral Candida albicans isolates from HIV-positive individuals have similar in vitro biofilm-forming ability and pathogenicity as invasive Candida isolates. BMC Microbiol (2011) 0.93
Asymptomatic oral yeast carriage and antifungal susceptibility profile of HIV-infected patients in Kunming, Yunnan Province of China. BMC Infect Dis (2013) 0.88
The Changing Epidemiology of Oropharyngeal Candidiasis in Patients with HIV/AIDS in the Era of Antiretroviral Therapy. AIDS Res Treat (2012) 0.86
Recent mouse and rat methods for the study of experimental oral candidiasis. Virulence (2013) 0.84
Oral lactoferrin protects against experimental candidiasis in mice. J Appl Microbiol (2014) 0.81
Fluconazole susceptibility and ERG11 gene expression in vaginal candida species isolated from Lagos Nigeria. Int J Mol Epidemiol Genet (2012) 0.77
Detection of species diversity in oral candida colonization and anti-fungal susceptibility among non-oral habit adult diabetic patients. J Nat Sci Biol Med (2014) 0.76
Antifungal Drug Susceptibility of Candida Species Isolated from HIV-Positive Patients Recruited at a Public Hospital in São Luís, Maranhão, Brazil. Front Microbiol (2017) 0.75
Species distribution & antifungal susceptibility pattern of oropharyngeal Candida isolates from human immunodeficiency virus infected individuals. Indian J Med Res (2016) 0.75
Candida antifungal drug resistance in sub-Saharan African populations: A systematic review. F1000Res (2016) 0.75
Phytochemical Characterization of Terminalia catappa Linn. Extracts and Their antifungal Activities against Candida spp. Front Microbiol (2017) 0.75
An in vitro study of antifungal drug susceptibility of Candida species isolated from human immunodeficiency virus seropositive and human immunodeficiency virus seronegative individuals in Lucknow population Uttar Pradesh. J Oral Maxillofac Pathol (2015) 0.75
Preclinical study of a cost-effective photodynamic therapy protocol for treating oral candidoses. Lasers Med Sci (2017) 0.75
The Candida albicans Inhibitory Activity of the Extract from Papaya (Carica papaya L.) Seed Relates to Mitochondria Dysfunction. Int J Mol Sci (2017) 0.75
Resistance of Candida species to fluconazole. Antimicrob Agents Chemother (1995) 9.04
Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis (1994) 5.44
Fluconazole resistance in Candida glabrata. Lancet (1988) 4.05
Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. J Antimicrob Chemother (1995) 2.83
Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis (1999) 2.34
Guide to epidemiology and diagnosis of oral mucosal diseases and conditions. World Health Organization. Community Dent Oral Epidemiol (1980) 2.08
Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients. AIDS (1994) 1.99
In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. Antimicrob Agents Chemother (1994) 1.95
The prevalence of oral lesions in HIV-infected homosexual and bisexual men: three San Francisco epidemiological cohorts. AIDS (1991) 1.81
Oropharyngeal candidiasis resistant to single-dose therapy with fluconazole in HIV-infected patients. AIDS (1994) 1.55
Application of flow cytometry to the study of HIV infection. AIDS (1990) 1.38
Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis. J Antimicrob Chemother (2000) 1.36
Decline in the rate of oral opportunistic infections following introduction of highly active antiretroviral therapy. J Oral Pathol Med (2000) 1.33
Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole. J Clin Microbiol (2002) 1.30
The effect of antiretroviral therapy on the prevalence of oral manifestations in HIV-infected patients: a UK study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2001) 1.24
Oral manifestations of HIV infection in children and adults receiving highly active anti-retroviral therapy [HAART] in Dar es Salaam, Tanzania. BMC Oral Health (2006) 1.22
Molecular epidemiology of recurrent oral candidiasis in human immunodeficiency virus-positive patients: evidence for two patterns of recurrence. J Infect Dis (1993) 1.18
Oral candidiasis as a clinical marker related to viral load, CD4 lymphocyte count and CD4 lymphocyte percentage in HIV-infected patients. J Oral Pathol Med (2002) 1.15
Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. Clin Infect Dis (2000) 1.12
Antifungal susceptibility of South African oral yeast isolates from HIV/AIDS patients and healthy individuals. Diagn Microbiol Infect Dis (2002) 1.09
Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues. Clin Infect Dis (1998) 1.09
Oral lesions in HIV/AIDS patients undergoing highly active antiretroviral treatment including protease inhibitors: a new face of oral AIDS? AIDS Patient Care STDS (2000) 1.09
Oropharyngeal carriage of Candida species in HIV-infected patients in India. Mycoses (2003) 1.08
Emergence of resistance of Candida albicans to clotrimazole in human immunodeficiency virus-infected children: in vitro and clinical correlations. J Clin Microbiol (2000) 1.06
Susceptibility pattern and molecular type of species-specific Candida in oropharyngeal lesions of Indian human immunodeficiency virus-positive patients. J Clin Microbiol (2004) 1.05
Effect of PI-HAART on the prevalence of oral lesions in HIV-1 infected patients. A Greek study. Oral Dis (2004) 1.04
Fluconazole susceptibility and strain variation of Candida albicans isolates from HIV-infected patients with oropharyngeal candidosis. J Antimicrob Chemother (1998) 1.00
Fungal infections associated with HIV infection. Oral Dis (2002) 1.00
Oral candidiasis and oral yeast carriage among institutionalised South African paediatric HIV/AIDS patients. Mycopathologia (2007) 0.99
In vitro susceptibility of oral Candida to seven antifungal agents. Oral Microbiol Immunol (2005) 0.99
Non-albicans oral candidosis in HIV-positive patients. J Antimicrob Chemother (1999) 0.98
Does long-term itraconazole prophylaxis result in in vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection? The National Institute of Allergy and Infectious Diseases Mycoses study group. Antimicrob Agents Chemother (2000) 0.96
Relationship between in vitro activities of amphotericin B and flucytosine and pH for clinical yeast and mold isolates. Antimicrob Agents Chemother (2005) 0.96
Occurrence of oral lesions in relation to clinical and immunological status among HIV-infected adult Tanzanians. Oral Dis (2000) 0.95
The treatment of oral candidiasis in a cohort of South African HIV/AIDS patients. SADJ (1999) 0.91
Species distribution and antifungal susceptibility profile of oral candida isolates from HIV-infected patients in the antiretroviral therapy era. Mycopathologia (2006) 0.91
Point prevalence, microbiology and fluconazole susceptibility patterns of yeast isolates colonizing the oral cavities of HIV-infected patients in the era of highly active antiretroviral therapy. J Antimicrob Chemother (2002) 0.89
Oral HIV lesions and oral health behaviour of HIV-positive patients attending the Queen Elizabeth II Hospital, Maseru, Lesotho. SADJ (2002) 0.89
Oropharyngeal candidiasis in patients with human immunodeficiency virus: correlation of clinical outcome with in vitro resistance, serum azole levels, and immunosuppression. Clin Infect Dis (2001) 0.88
Detection of Candida dubliniensis in Venezuela. Mycopathologia (2005) 0.80
A randomized trial of multivitamin supplements and HIV disease progression and mortality. N Engl J Med (2004) 5.68
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol (2004) 4.70
Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med (2008) 4.68
Multiple-triazole-resistant aspergillosis. N Engl J Med (2007) 3.33
Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis (2004) 3.02
Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet (2011) 2.98
Sex differences in antiretroviral treatment outcomes among HIV-infected adults in an urban Tanzanian setting. AIDS (2011) 2.85
Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg Infect Dis (2011) 2.84
In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother (2003) 2.80
A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. J Infect Dis (2008) 2.77
Stroke incidence in rural and urban Tanzania: a prospective, community-based study. Lancet Neurol (2010) 2.50
In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother (2002) 2.36
Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol (2009) 2.31
TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proc Natl Acad Sci U S A (2007) 2.28
Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother (2003) 2.09
Therapeutic drug monitoring of voriconazole. Ther Drug Monit (2008) 2.09
Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis (2013) 2.09
Azole-resistant central nervous system aspergillosis. Clin Infect Dis (2009) 1.94
Aspergillus fumigatus evades immune recognition during germination through loss of toll-like receptor-4-mediated signal transduction. J Infect Dis (2003) 1.91
In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother (2003) 1.85
Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis (2007) 1.83
Paradoxical increase in circulating Aspergillus antigen during treatment with caspofungin in a patient with pulmonary aspergillosis. Clin Infect Dis (2006) 1.79
Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence. PLoS One (2010) 1.77
Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis (2009) 1.73
Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus. PLoS One (2012) 1.71
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob Agents Chemother (2009) 1.69
Antifungal activity of some Tanzanian plants used traditionally for the treatment of fungal infections. J Ethnopharmacol (2006) 1.64
Comparison of clinical and parasitological data from controlled human malaria infection trials. PLoS One (2012) 1.64
Plasmodium falciparum infection causes proinflammatory priming of human TLR responses. J Immunol (2007) 1.63
Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species. Antimicrob Agents Chemother (2012) 1.62
Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg (2012) 1.62
Azole resistance in Aspergillus fumigatus: a growing public health concern. Curr Opin Infect Dis (2013) 1.59
Molecular epidemiology of Aspergillus fumigatus isolates recovered from water, air, and patients shows two clusters of genetically distinct strains. J Clin Microbiol (2003) 1.59
Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity. Proc Natl Acad Sci U S A (2013) 1.57
Screening of Tanzanian medicinal plants for anti-Candida activity. BMC Complement Altern Med (2006) 1.55
Multidrug resistance in Aspergillus fumigatus. N Engl J Med (2002) 1.54
Identification of four distinct genotypes of Candida dubliniensis and detection of microevolution in vitro and in vivo. J Clin Microbiol (2002) 1.49
Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother (2010) 1.49
Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob Agents Chemother (2011) 1.49
Selenium status is associated with accelerated HIV disease progression among HIV-1-infected pregnant women in Tanzania. J Nutr (2004) 1.47
Surveillance of HIV and syphilis infections among antenatal clinic attendees in Tanzania-2003/2004. BMC Public Health (2006) 1.47
Aspergillus calidoustus sp. nov., causative agent of human infections previously assigned to Aspergillus ustus. Eukaryot Cell (2008) 1.46
Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. Antimicrob Agents Chemother (2010) 1.45
Pseudomonas aeruginosa as a cause of 1,3-beta-D-glucan assay reactivity. Clin Infect Dis (2008) 1.43
Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery. Med Mycol (2008) 1.43
Toll-like receptor 4 Asp299Gly/Thr399Ile polymorphisms are a risk factor for Candida bloodstream infection. Eur Cytokine Netw (2006) 1.41
C-reactive protein independently predicts HIV-related outcomes among women and children in a resource-poor setting. AIDS (2007) 1.39
Identification of Paecilomyces variotii in clinical samples and settings. J Clin Microbiol (2010) 1.37
Successful treatment of Fusarium keratitis with cornea transplantation and topical and systemic voriconazole. Clin Infect Dis (2005) 1.36
Aspergillosis--and a misleading sensitivity result. Lancet (2007) 1.36
1,3-beta-D-glucan in patients receiving intravenous amoxicillin-clavulanic acid. N Engl J Med (2006) 1.35
Estimating and projecting HIV prevalence and AIDS deaths in Tanzania using antenatal surveillance data. BMC Public Health (2006) 1.35
Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models. Med Mycol (2005) 1.34
Aspergillus species intrinsically resistant to antifungal agents. Med Mycol (2010) 1.33
Utility of Aspergillus antigen detection in specimens other than serum specimens. Clin Infect Dis (2004) 1.33
Experience of initiating collaboration of traditional healers in managing HIV and AIDS in Tanzania. J Ethnobiol Ethnomed (2007) 1.32
Enumeration of CD4+ T-cells using a portable microchip count platform in Tanzanian HIV-infected patients. PLoS One (2011) 1.32
Antimicrobial activity and brine shrimp toxicity of extracts of Terminalia brownii roots and stem. BMC Complement Altern Med (2007) 1.27
Micronutrients in HIV-positive persons receiving highly active antiretroviral therapy. Am J Clin Nutr (2007) 1.27
Randomized, double-blind, placebo-controlled trial of selenium supplements among HIV-infected pregnant women in Tanzania: effects on maternal and child outcomes. Am J Clin Nutr (2008) 1.26
Functional and genetic evidence that the Mal/TIRAP allele variant 180L has been selected by providing protection against septic shock. Proc Natl Acad Sci U S A (2009) 1.25
Discovery of a HapE mutation that causes azole resistance in Aspergillus fumigatus through whole genome sequencing and sexual crossing. PLoS One (2012) 1.22
Two patients with cryptococcal meningitis and idiopathic CD4 lymphopenia: defective cytokine production and reversal by recombinant interferon- gamma therapy. Clin Infect Dis (2004) 1.22
Oral manifestations of HIV infection in children and adults receiving highly active anti-retroviral therapy [HAART] in Dar es Salaam, Tanzania. BMC Oral Health (2006) 1.22
Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations. PLoS One (2013) 1.17
In vitro release by Aspergillus fumigatus of galactofuranose antigens, 1,3-beta-D-glucan, and DNA, surrogate markers used for diagnosis of invasive aspergillosis. J Clin Microbiol (2006) 1.16
Molecular epidemiology of Aspergillus fumigatus isolates harboring the TR34/L98H azole resistance mechanism. J Clin Microbiol (2012) 1.16
Keratitis caused by Scedosporium apiospermum successfully treated with a cornea transplant and voriconazole. J Clin Microbiol (2003) 1.15
Azole resistance in Aspergillus fumigatus: a new challenge in the management of invasive aspergillosis? Future Microbiol (2011) 1.14
Iron deficiency and anemia predict mortality in patients with tuberculosis. J Nutr (2011) 1.14
Prevalence of hepatitis B co-infection and response to antiretroviral therapy among HIV-infected patients in Tanzania. AIDS (2013) 1.14
Comparison of the Etest and the sensititre colorimetric methods with the NCCLS proposed standard for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol (2002) 1.13
Early interferon-gamma response against Plasmodium falciparum correlates with interethnic differences in susceptibility to parasitemia between sympatric Fulani and Dogon in Mali. J Infect Dis (2010) 1.12
Multivitamin supplementation improves hematologic status in HIV-infected women and their children in Tanzania. Am J Clin Nutr (2007) 1.11
Memory-like IFN-γ response by NK cells following malaria infection reveals the crucial role of T cells in NK cell activation by P. falciparum. Eur J Immunol (2010) 1.10
1,25-dihydroxyvitamin D3 modulates cytokine production induced by Candida albicans: impact of seasonal variation of immune responses. J Infect Dis (2011) 1.10
International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations. Antimicrob Agents Chemother (2008) 1.07
Screening of traditionally used plants for in vivo antimalarial activity in mice. Afr J Tradit Complement Altern Med (2009) 1.06
Vitamin D(3) down-regulates proinflammatory cytokine response to Mycobacterium tuberculosis through pattern recognition receptors while inducing protective cathelicidin production. Cytokine (2011) 1.05
Emericella quadrilineata as cause of invasive aspergillosis. Emerg Infect Dis (2008) 1.05
In vitro susceptibilities of Zygomycota to polyenes. J Antimicrob Chemother (2002) 1.05
Continuous infusion of amphotericin B deoxycholate for the treatment of life-threatening Candida infections. Am J Respir Crit Care Med (2013) 1.05
The structure-function relationship of the Aspergillus fumigatuscyp51A L98H conversion by site-directed mutagenesis: the mechanism of L98H azole resistance. Fungal Genet Biol (2011) 1.05
Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosis. Antimicrob Agents Chemother (2002) 1.05
Non-culture-based diagnostics for opportunistic fungi. Infect Dis Clin North Am (2006) 1.04